2-(3-甲氧基苯氨基)-乙醇 | 2933-76-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(3-甲氧基苯氨基)-乙醇
• 英文名称: 2-((3-methoxyphenyl)amino)ethanol
• 英文别名: 2-(3-Methoxyphenylamino)ethanol；2-(3-methoxyanilino)ethanol
• CAS: 2933-76-8
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: QOVGKNPMRTVWRM-UHFFFAOYSA-N

物化性质

• 沸点：
  335.0±22.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  2-(3-甲氧基苯氨基)-乙醇 在 四丁基溴化铵 、 三苯基膦 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以82%的产率得到N-(2-bromoethyl)-3-methoxyaniline
  参考文献：
  名称：

  Development of Unsymmetrical Dyads As Potent Noncarbohydrate-Based Inhibitors against Human β-N-Acetyl-d-hexosaminidase

  摘要：

  Human beta-N-acetyl-D-hexosaminidase has gained much attention due to its roles in several pathological processes and been considered as potential targets for disease therapy. A novel and efficient skeleton, which was an unsymmetrical dyad containing naphthalimide and methoxyphenyl moieties with an alkylamine spacer linkage as a noncarbohydrate-based inhibitor, was synthesized, and the activities were valuated against human beta-N-acetyl-D-hexosaminidase. The most potent inhibitor exhibits high inhibitory activity with K-i values of 0.63 mu M. The straightforward synthetic manner of these unsymmetrical dyads and understanding of the binding model cold be advantageous for further structure optimization and development of new therapeutic agents for Hex-related diseases.

  DOI：

  10.1021/ml300475m
• 作为产物：
  描述：

  3-(3-methoxyphenyl)oxazolidin-2-one 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-(3-甲氧基苯氨基)-乙醇
  参考文献：
  名称：

  Bis-aryl Urea Derivatives as Potent and Selective LIM Kinase (Limk) Inhibitors

  摘要：

  The discovery/optimization of bis-aryl ureas as Limk inhibitors to obtain high potency and selectivity and appropriate pharmacokinetic properties through systematic SAR studies is reported. Docking studies supported the observed SAR. Optimized Limk inhibitors had high biochemical potency (IC50 < 25 nM), excellent selectivity against ROCK and JNK kinases (>400-fold), potent inhibition of cofilin phosphorylation in A7r5, PC-3, and CEM-SS T cells (IC50 < 1 mu M), and good in vitro and in vivo pharmacokinetic properties. In the profiling against a panel of 61 kinases, compound 18b at 1 mu M inhibited only Limk1 and STK16 with >= 80% inhibition. Compounds 18b and 18f were highly efficient in inhibiting cell-invasion/migration in PC-3 cells. In addition, compound 18w was demonstrated to be effective on reducing intraocular pressure (IOP) on rat eyes. Taken together, these data demonstrated that we had developed a novel class of bis-aryl urea derived potent and selective Limk inhibitors.

  DOI：

  10.1021/jm501680m

文献信息

• TRICYCLIC PIPERAZINE DERIVATIVE
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20160083391A1

  公开（公告）日：2016-03-24

  Disclosed are compounds useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.

  揭示了作为磷酸二酯酶1（PDE1）抑制剂有用的化合物，以及它们的组合物和使用方法。
• Room-Temperature Practical Copper-Catalyzed Amination of Aryl Iodides
  作者：Christopher Deldaele、Gwilherm Evano

  DOI：10.1002/cctc.201501375

  日期：2016.4.6

  An efficient and highly practical procedure is reported for the Ullmann–Goldberg‐type copper‐catalyzed amination of aryl iodides. By using a combination of copper iodide and proline in the presence of an excess of an amine, a wide range of aryl iodides can be readily aminated at room temperature. The reaction proceeds well regardless of the electronic properties of the starting aryl iodide and the

  据报道，Ullmann–Goldberg型铜催化芳基碘化物的胺化反应是一种有效且高度实用的程序。通过在过量胺的存在下使用碘化铜和脯氨酸的组合，可以在室温下容易地胺化各种各样的芳基碘。无论起始碘代芳基化物的电子性质如何，反应都进行得很好，并且在大多数情况下不需要通过柱色谱法纯化就可以得到胺化产物。由于其效率和反应条件的温和性，该胺化反应还可扩展至在室温下胺化复杂的芳基碘化物。
• INDAZOLEPROPIONIC ACID AMIDE COMPOUND
  申请人：Yamaguchi Tetsuo

  公开号：US20120016117A1

  公开（公告）日：2012-01-19

  Disclosed is a compound which is useful in preventing and treating cardiac arrhythmia such as atrial fibrillation. A compound represented by formula (1) or a pharmaceutically acceptable salt of the same. In formula (1), ring X represents benzene or pyridine; R 1 represents an optionally substituted alkyl group; R 2 represents an optionally substituted aryl group, an optionally substituted heterocyclic group, an optionally substituted arylalkyl group or an optionally substituted heterocyclic group-substituted alkyl group; R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 represent each hydrogen or an alkyl group, provided that R 3 and R 5 may be bonded to each other to form, together with the carbon atom adjacent thereto, a cycloalkyl group; and m represents 0 or 1.

  本申请揭示了一种化合物，用于预防和治疗心律失常，如心房纤颤。该化合物由式（1）表示，或者其药学上可接受的盐。在式（1）中，环X代表苯或吡啶；R1代表可选择地取代的烷基基团；R2代表可选择地取代的芳基基团，可选择地取代的杂环基团，可选择地取代的芳基烷基基团或可选择地取代的杂环基团取代的烷基基团；R3、R4、R5、R6、R7、R8和R9分别代表氢或烷基基团，但R3和R5可以结合在一起，与相邻的碳原子一起形成环烷基基团；m代表0或1。
• Pyridinium derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd

  公开号：US04962113A1

  公开（公告）日：1990-10-09

  Novel pyridinium derivatives represented by the formula (I): ##STR1## wherein ##STR2## is an optionally substituted pyridinium ring; R.sup.1 is a lower alkyl group or aralkyl group; R.sup.7 and R.sup.10 are independently hydrogen, a lower alkyl group, aryl group or aralkyl group; l is 0 or 1; R.sup.5 is a phenylene group or an alkylene group which may be substituted; R.sup.11 is an alkyl group or aryl group; X is a group of the formula: --CH.sub.2 OCH.sub.2 -- or a group of the formula: ##STR3## wherein R.sup.6 is hydrogen, a lower alkyl or a lower alkoxy, and m is an integer of 0 to 3; U is a group of the formula: ##STR4## wherein R.sup.4 is hydrogen, a lower alkyl group, aryl group or aralkyl group; Y and Z are independently a divalent chain group consisting of one to six members which is selected from the class consisting of groups of the formulae: ##STR5## wherein R is hydrogen, a lower alkyl group, acyl group or aryl group and at least one of which is a group of the formula: ##STR6## with the proviso that R may be the same or different from each other, or may form a ring together when two or more groups of the formula: ##STR7## are present, that R may be bonded to R.sup.4 when Y contains a group of the formula: ##STR8## and that R may be bonded to R.sup.11 when Z contains a group of the formula: ##STR9## and W.sup..crclbar. is a counter anion; are useful as a platelet activating factor antagonist.

  新型吡啶盐衍生物的结构如下（I）：##STR1##其中##STR2##是一个可选择取代的吡啶环；R.sup.1是一个低碳烷基或芳基烷基；R.sup.7和R.sup.10独立地是氢、低碳烷基、芳基或芳基烷基；l为0或1；R.sup.5是一个苯基或可能被取代的烷基；R.sup.11是一个烷基或芳基；X是一个式子：--CH.sub.2 OCH.sub.2 --或一个式子：##STR3##其中R.sup.6是氢、低碳烷基或低烷氧基，m是0到3的整数；U是一个式子：##STR4##其中R.sup.4是氢、低碳烷基、芳基或芳基烷基；Y和Z独立地是由1到6个成员组成的二价链状基团，选自下列式：##STR5##其中R是氢、低碳烷基、酰基或芳基，至少有一个是下列式之一：##STR6##但要求R可以相同也可以不同，或者当存在两个或更多的下列式之一：##STR7##时，R可以一起形成环；当Y包含一个下列式之一：##STR8##时，R可以与R.sup.4结合；当Z包含一个下列式之一：##STR9##时，R可以与R.sup.11结合；W.sup..crclbar.是一个反离子；这些化合物可用作血小板活化因子拮抗剂。
• Palladium-Catalyzed Intramolecular Carbene Insertion into C(sp³ )−H Bonds
  作者：Daniel Solé、Francesco Mariani、M.-Lluïsa Bennasar、Israel Fernández

  DOI：10.1002/anie.201602020

  日期：2016.5.23

  palladium‐catalyzed carbene insertion into C(sp3)−H bonds leading to pyrrolidines was developed. The coupling reaction can be catalyzed by both Pd0 and PdII, is regioselective, and shows a broad functional group tolerance. This reaction is the first example of palladium‐catalyzed C(sp3)−C(sp3) bond assembly starting from diazocarbonyl compounds. DFT calculations revealed that this direct C(sp3)−H bond functionalization

  开发了钯催化的卡宾插入C（sp 3）-H键导致吡咯烷。偶合反应可被Pd 0和Pd II催化，具有区域选择性，并显示出宽泛的官能团耐受性。该反应是从重氮羰基化合物开始的钯催化的C（sp 3）-C（sp 3）键组装的第一个例子。DFT计算表明，这种直接的C（sp 3）-H键官能化反应涉及前所未有的一致的金属化-去质子化步骤。